0
Deep & Emerging Tech·November 17, 2026·1 min read

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

Share

The FDA asking for another lung‑cancer trial after prior disclosures shows how quickly biotech narratives can invert when regulators add new data demands. If your pipeline depends on single‑study readouts, revisit cash runway and partnership options assuming at least one extra trial cycle.